Kriya launches first global AAV gene therapy trial for type 1 diabetes
Updated
Updated · Medical Brief · Apr 22
Kriya launches first global AAV gene therapy trial for type 1 diabetes
6 articles · Updated · Medical Brief · Apr 22
The PROGRESS study will enroll adults with type 1 diabetes for a one-time intramuscular injection of KRIYA-839, following them for one year to assess safety and efficacy.
This phase 1 trial uses an AAV vector to deliver glucokinase and insulin genes into thigh muscle, aiming for durable insulin production without chronic immunosuppression.
If successful, this approach could offer a functional cure for many with type 1 diabetes, expanding treatment beyond those eligible for current islet transplants and potentially benefiting a broad patient population.
With past AAV trials leading to patient deaths, what makes this new diabetes gene therapy different?
As gene therapy faces a market rebound, can this diabetes trial finally deliver a commercial blockbuster?
Can muscle cells truly replace the pancreas to safely regulate blood sugar for a lifetime?
How will regulators balance hope for a cure with the known immune risks of AAV gene therapies?
If the therapy works, will its effects last for life or eventually fade over time?
KRIYA-839 Gene Therapy for T1D: Single-Dose AAV Treatment Aims to Achieve Durable Insulin Production Without Immunosuppression
Overview
In April 2026, Kriya Therapeutics launched the PROGRESS trial, the first global study testing KRIYA-839, a single-dose AAV gene therapy for adults with type 1 diabetes who struggle to control blood sugar despite advanced insulin delivery. The therapy delivers insulin and glucokinase genes directly to muscle cells, enabling them to produce insulin and sense glucose levels, creating a natural, glucose-responsive system. Preclinical studies showed durable blood sugar normalization without chronic immunosuppression. The trial includes a one-year follow-up to assess safety and effectiveness, with initial results expected in 2027. If successful, KRIYA-839 could offer a transformative, long-lasting alternative to current treatments, reducing daily management burdens and improving quality of life.